Format

Send to

Choose Destination
See comment in PubMed Commons below
BMC Neurol. 2008 Mar 26;8:4. doi: 10.1186/1471-2377-8-4.

Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients.

Author information

1
Department of Neurosciences, Norwegian University of Science and Technology, Trondheim, Norway. Erling.Tronvik@ntnu.no

Abstract

BACKGROUND:

The main objective of this study was to investigate the angiotensin converting enzyme (ACE) genotype as a possible risk factor for migraine (both with and without aura) compared to controls. We also wanted to examine whether a clinical response to an ACE inhibitor, lisinopril, or an angiotensin II receptor blocker, candesartan, in migraine prophylaxis was related to ACE genotype.

METHODS:

347 migraine patients aged 18-68 (155 migraine without aura (MoA), 187 migraine with aura (MwA) and 5 missing aura subgroup data) and 403 healthy non-migrainous controls > 40 years of age were included in the study. A polymerase chain reaction (PCR) was performed on the genomic DNA samples to obtain the ACE insertion (I)/deletion(D) polymorphisms.

RESULTS:

No significant differences between migraine patients and controls were found with regard to ACE genotype and allele distributions. Furthermore, there was no significant difference between the controls and the MwA or MoA subgroups.

CONCLUSION:

In our sample there is no association between ACE genotype or allele frequency and migraine. In addition, ACE genotype in our experience did not predict the clinical response to lisinopril or candesartan used as migraine prophylactics.

PMID:
18366776
PMCID:
PMC2311324
DOI:
10.1186/1471-2377-8-4
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center